NYSE : TMO
Thermo Fisher Scientific Inc. — Key statistics
Healthcare · Diagnostics & Research · United States
Last price 697 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 258.25B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 258.25B |
| Enterprise Value | 293.56B |
Dates
| Measure | Value |
|---|
| Earnings Date | Oct 21, 2026 |
| Ex-Dividend Date | Sep 15, 2026 |
Shares
| Measure | Value |
|---|
| Current Share Class | 370.52M |
| Shares Outstanding | 370.52M |
| Shares Change (YoY) | -1.91% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 0.12% |
| Owned by Institutions (%) | 91.84% |
| Float | 368.83M |
Ratios
| Measure | Value |
|---|
| PE Ratio | 36.74 |
| Forward PE | 25.89 |
| PS Ratio | 5.45 |
| Forward PS | 5.19 |
| PB Ratio | 4.72 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 34.00 |
| P/OCF Ratio | 27.70 |
| PEG Ratio | 2.62 |
Evratios
| Measure | Value |
|---|
| EV / Earnings | 41.51 |
| EV / Sales | 6.20 |
| EV / EBITDA | 24.20 |
| EV / EBIT | 32.52 |
| EV / FCF | 38.65 |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 1.81 |
| Quick Ratio | 1.23 |
| Debt / Equity | 0.75 |
| Debt / EBITDA | 3.28 |
| Debt / FCF | 5.45 |
| Interest Coverage | 5.87 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | 13.38% |
| Return on Assets (ROA) | 5.19% |
| Return on Invested Capital (ROIC) | 9.00% |
| Return on Capital Employed (ROCE) | 9.02% |
| Weighted Average Cost of Capital (WACC) | 8.29% |
| Revenue Per Employee | $378,808 |
| Profits Per Employee | $56,576 |
| Employee Count | 125,000 |
| Asset Turnover | 0.44 |
| Inventory Turnover | 4.88 |
Taxes
| Measure | Value |
|---|
| Income Tax | 743.00M |
| Effective Tax Rate | 9.48% |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.88 |
| 52-Week Price Change | +24.84% |
| 50-Day Moving Average | 654.65 |
| 200-Day Moving Average | 551.37 |
| Relative Strength Index (RSI) | 59.15 |
| Average Volume (20 Days) | 2,372,465 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 4.89M |
| Short Previous Month | 5.02M |
| Short % of Shares Out | 1.32% |
| Short % of Float | 1.33% |
| Short Ratio (days to cover) | 1.98 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 47.35B |
| Gross Profit | 19.54B |
| Operating Income | 9.03B |
| Pretax Income | 7.84B |
| Net Income | 7.07B |
| EBITDA | 12.13B |
| EBIT | 9.03B |
| Earnings Per Share (EPS) | $18.97 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 6.06B |
| Total Debt | 41.37B |
| Net Cash | -35.31B |
| Net Cash Per Share | -$95.30 |
| Equity (Book Value) | 54.90B |
| Book Value Per Share | 147.80 |
| Working Capital | 11.45B |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | 9.32B |
| Capital Expenditures | -1.73B |
| Depreciation & Amortization | 3.11B |
| Net Borrowing | 6.35B |
| Free Cash Flow | 7.60B |
| FCF Per Share | $20.50 |
Margins
| Measure | Value |
|---|
| Gross Margin | 41.26% |
| Operating Margin | 19.06% |
| Pretax Margin | 16.55% |
| Profit Margin | 14.94% |
| EBITDA Margin | 25.62% |
| EBIT Margin | 19.06% |
| FCF Margin | 16.04% |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | $1.88 |
| Dividend Yield | 0.27% |
| Dividend Growth (YoY) | 9.52% |
| Years of Dividend Growth | 8 |
| Payout Ratio | 9.91% |
| FCF Payout Ratio | 9.17% |
| Buyback Yield | 1.91% |
| Shareholder Yield | 2.18% |
| Earnings Yield | 2.72% |
| FCF Yield | 2.94% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $752.12 |
| Price Target Difference | 7.91% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 27 |
| Revenue Growth Forecast (3Y) | 6.44% |
| EPS Growth Forecast (3Y) | 10.36% |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Jun 6, 1996 |
| Split Type | Forward |
| Split Ratio | 1.5:1 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 3.63 |
| Piotroski F-Score | 6 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside | |